Calorimetry, IndirectNCT04482556
Comparison of the Q-NRG+ Indirect Calorimetry Device Versus the V(Max) Encore Device in Mechanically Ventilated Children
A study testing Q-NRG+ Indirect Calorimetry Device and V(max) Encore Indirect Calorimetry Device in people with Calorimetry, Indirect and Oxygen Consumption, run by Boston Children's Hospital at 1 site in United States.
Trial summary
The overarching aim of this proposal is to examine the feasibility of the Q-NRG+ indirect calorimetry device and its agreement with (Vmax) Encore indirect calorimetry device in mechanically ventilated children. Read more about this study
- Who is it for?
- Ages 10 to 18 years
- Conditions the study is for
- Calorimetry, Indirect, Oxygen Consumption, Metabolism
- What is being tested?
- Q-NRG+ Indirect Calorimetry Device and V(max) Encore Indirect Calorimetry Device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2020to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Children mechanically ventilated with endotracheal tube of tracheostomy in standard ventilatory modes such as SIMV-PC, SIMV-VC or PRVC
- Age > 10 years AND weight > 10kg
- FIO2 < 60%
- PEEP < 8
- ETT leak < 10%
- The attending physician of record plans to order indirect calorimetry and considers research activity safe
Who cannot join
- Hemodynamic instability (hypotension according to PALS/ACLS formula or requiring 2 or greater vasoactive infusions)
- Presence of chest tubes with ongoing air leak
- Patients requiring ECMO support
- Patients undergoing end-of-life care
- Primary provider declines enrollment.
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Boston Children's Hospital
Boston, Massachusetts, 02115
Ben Albert, MD, 617-355-7327
About this study
The overarching aim of this proposal is to examine the feasibility of the Q-NRG+ indirect calorimetry device and its agreement with (Vmax) Encore indirect calorimetry device in mechanically ventilated children. The overall hypothesis of this study is that the Q-NRG+ will provide minute-to-minute oxygen consumption (VO2) and carbon dioxide production (CO2) measurements that are in agreement with those obtained by the standard indirect calorimetry device currently used at our institution (Vmax Encore).
Read the detailed description
Indirect calorimetry allows accurate measurement of energy expenditure in this population but current technology is cumbersome and time-consuming, and has many limitations that exclude a majority of criticaly ill children. A new device was recently developed to address some of the limitations of IC devices and is widely endorsed for IC measurements in critically ill adults. The Q-NRG+ IC device incorporates an easier gas calibration technique to facilitate faster start up, and a micro-mixing chamber (2ml) allows rapid achievement of steady state gas exchange measurement. The device may address some of the current barriers for the use of indirect calorimetry in critically ill children. A device with short calibration time and reliable measurements could enhance the ability of clinicians to deliver individualized energy prescriptions for patients.
Description of Study Treatments
Following informed consent, the following steps will be followed for the study procedure:
- The two testing indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient, therefore it will be decided the V(max) will be tested first in the first enrolled patient then the Q-NRG+ second. Each enrolled patient subsequently will alternate in which device is tested first.
- The first device will be connected to the patient, after calibration, and data collection will begin for a maximum duration of 30 minutes.
- At the end of the first testing period, the first device will be disconnected and the second device will be connected to the study patient.
- Data collection for the second device will then begin for a maximum duration of 30 minutes.
- At the end of the testing period, the data collected for the V(max) device will be discussed with the parents and the clinical team. Data collected from the Q-NRG+ will not be shared with the clinical team or family as this device is still being investigated in the pediatric population.
- The study will then conclude.
Definitions of Outcomes/Endpoints The primary variables to be collected are steady state measurements of VO2 and VCO2 from both indirect calorimetry devices. Steady state will be defined as a period of greater than five minutes with coefficient of variation of the VO2 and VCO2 measurements of less than 10%. If steady state is not achieved, energy calculations will not be included in data analysis. Secondary variables to be collected include total time to obtain indirect calorimetry measurement, from arrival at the bedside to completion of the study. Steady state conditions will be defined using existing institutional practice.
Data Collection Methods and Assessments Descriptive characteristics will also be collected for each patient including age, weight, height, diagnosis, severity of illness, length of ICU stay, vital signs, and ventilator settings. We will also collect endotracheal tube size, presence of cuff, leak percentage. We will also collect information about medications, including inotropes and vasopressors, sedation medications (as well as SBS score) and nutrition parameters. Markers of inflammation, WBC and CRP will be collected from the patient chart.
Statistical Analysis Descriptive statistics will be computed for measured REE, VO2 and VCO2 and Bland-Altman analysis will be utilized to quantify the mean bias and limits of agreement between devices. Acceptable limits of agreement between the devices will be +/- 20%. VO2, CO2 will be reported as means (SD). The time to steady state and total time of IC measurement will be compared using a T-test (if normally distributed) or Mann-Whitney U-test (if not normally distributed).
- Being tested
- Q-NRG+ Indirect Calorimetry Device, V(max) Encore Indirect Calorimetry Device
- Keywords
- Pediatrics, Indirect Calorimetry, Enteral Nutrition, Metabolism, Critical Care
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Q-NRG+ Indirect Calorimetry DeviceDevice
The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
V(max) Encore Indirect Calorimetry DeviceDevice
The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
| Study group | Role | What they receive |
|---|---|---|
| Q-NRG+ Indirect Calorimetry Device | Other | Q-NRG+ device will be compared to current V(max) device in each enrolled patient in subsequent, alternating fashion. Receives: Device: Q-NRG+ Indirect Calorimetry Device |
| V(max) Encore Indirect Calorimetry Device | Other | V(max) Encore device, currently institution's standard device, will be compared to Q-NRG+ device in each enrolled patient in subsequent, alternating fashion. Receives: Device: V(max) Encore Indirect Calorimetry Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean bias and limits of agreement between measured oxygen consumption (VO2) and carbon dioxide elimination (VCO2) in mechanically ventilated children assessed using the Q-NRG+ indirect calorimetry device and the V(max) Encore indirect calorimetry device.
In mechanically ventilated children, we will describe the mean bias and limits of agreement in measurements using both indirect calorimeters. Our hypothesis is that the measurement of oxygen consumption (VO2) and carbon dioxide production (VCO2) with the 2 devices will have a low mean bias and will be within clinically acceptable limits of agreement.
Measured: 1 hour/participant
Calculated total testing time, including calibration, required to complete a steady state indirect calorimetry measurement using the Q-NRG+ device and the V(max) Encore.
Total time lapsed, including time for patient data input, warm-up, calibration, and gas exchange measurements in steady state will be recorded. Our hypothesis is that the time required to obtain energy expenditure with Q-NRG+ device will be significantly shorter as compared to the Vmax Encore device.
Measured: 1 hour/participant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2020
- Study start1 Jan 2020
- Primary completion1 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Calorimetry, IndirectStudies of the same condition, open and under way.
- More trials run by Boston Children's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Boston Children's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ben D. Albert, MD, Boston Children's Hospital
- Investigators
- Nilesh M Mehta, MD, Study director, Boston Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04482556
- Sponsor's protocol ID
- IRB-P00033440
- Status last verified
- Dec 2023
- First submitted
- 17 Jul 2020
- Last updated
- 3 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Q-NRG+ Indirect Calorimetry Device Versus the V(Max) Encore Device in Mechanically Ventilated Children
- ClinicalTrials.gov ID
- NCT04482556
- Acronym / sponsor ID
- IRB-P00033440
- Keywords
- Pediatrics, Indirect Calorimetry, Enteral Nutrition, Metabolism, Critical Care
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Boston Children's HospitalUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 22 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching aim of this proposal is to examine the feasibility of the Q-NRG+ indirect calorimetry device and its agreement with (Vmax) Encore indirect calorimetry device in mechanically ventilated children. The overall hypothesis of this study is that the Q-NRG+ will provide minute-to-minute oxygen consumption (VO2) and carbon dioxide production (CO2) measurements that are in agreement with those obtained by the standard indirect calorimetry device currently used at our institution (Vmax Encore).
Detailed description
Indirect calorimetry allows accurate measurement of energy expenditure in this population but current technology is cumbersome and time-consuming, and has many limitations that exclude a majority of criticaly ill children. A new device was recently developed to address some of the limitations of IC devices and is widely endorsed for IC measurements in critically ill adults. The Q-NRG+ IC device incorporates an easier gas calibration technique to facilitate faster start up, and a micro-mixing chamber (2ml) allows rapid achievement of steady state gas exchange measurement. The device may address some of the current barriers for the use of indirect calorimetry in critically ill children. A device with short calibration time and reliable measurements could enhance the ability of clinicians to deliver individualized energy prescriptions for patients.
Description of Study Treatments
Following informed consent, the following steps will be followed for the study procedure:
- The two testing indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient, therefore it will be decided the V(max) will be tested first in the first enrolled patient then the Q-NRG+ second. Each enrolled patient subsequently will alternate in which device is tested first.
- The first device will be connected to the patient, after calibration, and data collection will begin for a maximum duration of 30 minutes.
- At the end of the first testing period, the first device will be disconnected and the second device will be connected to the study patient.
- Data collection for the second device will then begin for a maximum duration of 30 minutes.
- At the end of the testing period, the data collected for the V(max) device will be discussed with the parents and the clinical team. Data collected from the Q-NRG+ will not be shared with the clinical team or family as this device is still being investigated in the pediatric population.
- The study will then conclude.
Definitions of Outcomes/Endpoints The primary variables to be collected are steady state measurements of VO2 and VCO2 from both indirect calorimetry devices. Steady state will be defined as a period of greater than five minutes with coefficient of variation of the VO2 and VCO2 measurements of less than 10%. If steady state is not achieved, energy calculations will not be included in data analysis. Secondary variables to be collected include total time to obtain indirect calorimetry measurement, from arrival at the bedside to completion of the study. Steady state conditions will be defined using existing institutional practice.
Data Collection Methods and Assessments Descriptive characteristics will also be collected for each patient including age, weight, height, diagnosis, severity of illness, length of ICU stay, vital signs, and ventilator settings. We will also collect endotracheal tube size, presence of cuff, leak percentage. We will also collect information about medications, including inotropes and vasopressors, sedation medications (as well as SBS score) and nutrition parameters. Markers of inflammation, WBC and CRP will be collected from the patient chart.
Statistical Analysis Descriptive statistics will be computed for measured REE, VO2 and VCO2 and Bland-Altman analysis will be utilized to quantify the mean bias and limits of agreement between devices. Acceptable limits of agreement between the devices will be +/- 20%. VO2, CO2 will be reported as means (SD). The time to steady state and total time of IC measurement will be compared using a T-test (if normally distributed) or Mann-Whitney U-test (if not normally distributed).
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Q-NRG+ Indirect Calorimetry Device | Other | Device: Q-NRG+ Indirect Calorimetry DeviceQ-NRG+ device will be compared to current V(max) device in each enrolled patient in subsequent, alternating fashion. |
| V(max) Encore Indirect Calorimetry Device | Other | Device: V(max) Encore Indirect Calorimetry DeviceV(max) Encore device, currently institution's standard device, will be compared to Q-NRG+ device in each enrolled patient in subsequent, alternating fashion. |
Who may qualify
- Ages
- 10 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (6 listed)
- Children mechanically ventilated with endotracheal tube of tracheostomy in standard ventilatory modes such as SIMV-PC, SIMV-VC or PRVC
- Age > 10 years AND weight > 10kg
- FIO2 < 60%
- PEEP < 8
- ETT leak < 10%
Key exclusion criteria (5 listed)
- Hemodynamic instability (hypotension according to PALS/ACLS formula or requiring 2 or greater vasoactive infusions)
- Presence of chest tubes with ongoing air leak
- Patients requiring ECMO support
- Patients undergoing end-of-life care
- Primary provider declines enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Q-NRG+ Indirect Calorimetry DeviceThe two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first. | Device | Q-NRG+ Indirect Calorimetry Device |
| V(max) Encore Indirect Calorimetry DeviceThe two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first. | Device | V(max) Encore Indirect Calorimetry Device |
Primary outcome
Mean bias and limits of agreement between measured oxygen consumption (VO2) and carbon dioxide elimination (VCO2) in mechanically ventilated children assessed using the Q-NRG+ indirect calorimetry device and the V(max) Encore indirect calorimetry device.
Time frame: 1 hour/participant
In mechanically ventilated children, we will describe the mean bias and limits of agreement in measurements using both indirect calorimeters. Our hypothesis is that the measurement of oxygen consumption (VO2) and carbon dioxide production (VCO2) with the 2 devices will have a low mean bias and will be within clinically acceptable limits of agreement.
Calculated total testing time, including calibration, required to complete a steady state indirect calorimetry measurement using the Q-NRG+ device and the V(max) Encore.
Time frame: 1 hour/participant
Total time lapsed, including time for patient data input, warm-up, calibration, and gas exchange measurements in steady state will be recorded. Our hypothesis is that the time required to obtain energy expenditure with Q-NRG+ device will be significantly shorter as compared to the Vmax Encore device.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Calorimetry, Indirect
RecruitingPhase 4
Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
Obesity (Disorder)
Active, not recruitingObservational study
Resting Metabolic Rate in Bodybuilders Using Performance-Enhancing Drugs
Athlete Assessment, Body Composition
Not yet recruiting
Inter-Individual Variability in Early Diet-Induced Thermogenesis After a Standardized Meal
Diet-induced Thermogenesis
RecruitingObservational study
Within-Individual Variability of Resting Metabolic Rate Over 12 Weeks
Resting Metabolic Rate, Energy Metabolism
Recruiting
Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill Run
Exercise Physiology, Nutritional Supplementation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nilesh M Mehta, MD study director
Boston Children's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Q-NRG+ Indirect Calorimetry Device and V(max) Encore Indirect Calorimetry Device in people with Calorimetry, Indirect and Oxygen Consumption, run by Boston Children's Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ben D Albert, MD (617-355-7327, ben.albert@childrens.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean bias and limits of agreement between measured oxygen consumption (VO2) and carbon dioxide elimination (VCO2) in mechanically ventilated children assessed using the Q-NRG+ indirect calorimetry device and the V(max) Encore indirect calorimetry device. (time frame: 1 hour/participant). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2024.